Log in

NASDAQ:KZIA - Kazia Therapeutics Stock Price, Forecast & News

+0.02 (+0.50 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
Now: $4.06
50-Day Range
MA: $4.28
52-Week Range
Now: $4.06
Volume5,823 shs
Average Volume6,960 shs
Market Capitalization$25.25 million
P/E RatioN/A
Dividend YieldN/A
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KZIA



Sales & Book Value

Annual Sales$1.12 million
Book Value$1.63 per share



Market Cap$25.25 million
Next Earnings DateN/A
OptionableNot Optionable

Receive KZIA News and Ratings via Email

Sign-up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter.

Kazia Therapeutics (NASDAQ:KZIA) Frequently Asked Questions

What is Kazia Therapeutics' stock symbol?

Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA."

Has Kazia Therapeutics been receiving favorable news coverage?

News coverage about KZIA stock has trended very positive recently, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Kazia Therapeutics earned a news sentiment score of 3.1 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Kazia Therapeutics.

Who are some of Kazia Therapeutics' key competitors?

What other stocks do shareholders of Kazia Therapeutics own?

Who are Kazia Therapeutics' key executives?

Kazia Therapeutics' management team includes the folowing people:
  • Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director (Age 46)
  • Ms. Gabrielle Heaton, Director of Fin. & Admin.
  • Ms. Catherine Jane Hill, Company Sec. (Age 60)
  • Kym Robins, Director of Marketing & Communications
  • Dr. Justine R. Stehn B.Sc (Hons), Ph.D., Director of ATM Program

How do I buy shares of Kazia Therapeutics?

Shares of KZIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kazia Therapeutics' stock price today?

One share of KZIA stock can currently be purchased for approximately $4.06.

How big of a company is Kazia Therapeutics?

Kazia Therapeutics has a market capitalization of $25.25 million and generates $1.12 million in revenue each year. The company earns $-7,340,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. View Additional Information About Kazia Therapeutics.

What is Kazia Therapeutics' official website?

The official website for Kazia Therapeutics is http://www.kaziatherapeutics.com/.

How can I contact Kazia Therapeutics?

Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The company can be reached via phone at 61-2-9472-4101 or via email at [email protected]

MarketBeat Community Rating for Kazia Therapeutics (NASDAQ KZIA)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  177
MarketBeat's community ratings are surveys of what our community members think about Kazia Therapeutics and other stocks. Vote "Outperform" if you believe KZIA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KZIA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: Bond

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel